Malignant Neoplasms
15
5
6
2
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
13.3%
2 terminated out of 15 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (15)
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
A Study of DEG6498 in Participants With Solid Tumors
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
A Multi Center Study of Sexual Toxicities After Radiotherapy
A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors
Validation of the Italian Version of the PRO-CTCAE
A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors
A Phase I Study Evaluating the Safety of Stereotactic Central Ablative Radiation Therapy (SCART) for Bulky Metastatic or Recurrent Cancer
Efficacy and Safety of the Paclitaxel Eluting Covered Biliary Stent to the Common Covered Metallic Biliary Stent
Patency and Safety of the Drug Eluting Covered Biliary Stent Comparing to the Common Covered Biliary Stent
The Clinical Study of Modern Therapies on Flora in Body Fluids and Blood of Malignant Tumor Patients
Community Cancer Centers Pilot Patient Survey